PXS Provexis plc
Provexis plc, together with its subsidiaries, develops, licenses, and sells functional foods, medical foods, and dietary supplements worldwide. It provides syrup and powder versions of Fruitflow, a tomato extract that reduces the propensity for aberrant blood clotting typically associated with cardiovascular diseases, such as heart attack and stroke used in various foods, beverages, and dietary supplement formats. The company also provides Fruitflow+ Omega-3, a dietary supplement product. It sells its products through e-commerce website and distributors. Provexis plc was founded in 1999 and is based in Reading, the United Kingdom.…
Industry Peers
Drug Manufacturers - Specialty & GenericKey Statistics
About Provexis (LON: PXS)
›
Provexis (LON: PXS) is listed on the London Stock Exchange, where its shares trade in pence sterling (GBp). It belongs to the Drug Manufacturers - Specialty & Generic industry, part of the Healthcare sector, and reports about 2 employees.
The shares were at 0.7050 GBp on 19 November 2026, up 23.7% over 52 weeks. Its 52-week range is 0.5550 GBp to 1.550 GBp: the price is 54.5% below the high and 27.0% above the low.
Its market capitalisation is 16.54M GBP.
Provexis reports return on equity of -45.5%, an operating margin of -40.5% and revenue up 77.6% year over year.
It holds more cash than debt, a net cash position of 893.14K GBP. Its Piotroski F-score is 4 out of 9, an average reading of its financial health.